Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy - PubMed (original) (raw)

Randomized Controlled Trial

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy

David H Henry et al. Oncologist. 2007 Feb.

Free article

Abstract

Purpose: To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa.

Patients and methods: In this open-label, multicenter trial, 187 patients with chemotherapy-related anemia (Hb <11 g/dl; serum ferritin > or =100 ng/ml or transferrin saturation > or =15%) scheduled to receive chemotherapy and epoetin alfa (40,000 U subcutaneously weekly) were randomized to 8 weeks of 125 mg of IV FG weekly, 325 mg of oral ferrous sulfate three times daily, or no iron. The primary outcome was a change in Hb from baseline to endpoint, first whole-blood or red blood cell transfusion, or study withdrawal.

Results: One hundred twenty-nine patients were evaluable for efficacy (FG, n = 41; oral iron, n = 44; no iron, n = 44). Mean increase in Hb was 2.4 g/dl (95% confidence interval [CI], 2.1-2.7) for FG (p = .0092 vs. oral iron; p = .0044 vs. no iron), 1.6 g/dl (95% CI, 1.1-2.1) for oral iron (p =.7695 vs. no iron), and 1.5 g/dl (95% CI, 1.1-1.9) for no iron. Hb response (increase > or =2 g/dl) was 73% for FG (p = .0099 vs. oral iron; p = .0029 vs. no iron), 46% for oral iron (p = .6687 vs. no iron), and 41% for no iron. FG was well tolerated.

Conclusion: For cancer patients with chemotherapy-related anemia receiving epoetin alfa, FG produces a significantly greater increase in Hb and Hb response compared with oral iron or no iron, supporting more aggressive treatment with IV iron supplementation for these patients.

PubMed Disclaimer

Cited by

Recognition of thrombotic risk of thrombocytosis in iron deficiency.
Al-Samkari H, Kessler CM, Auerbach M. Al-Samkari H, et al. Haematologica. 2021 Mar 1;106(3):661-663. doi: 10.3324/haematol.2020.270496. Haematologica. 2021. PMID: 33645945 Free PMC article. No abstract available.
Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer.
Vadhan-Raj S, Dahl NV, Bernard K, Li Z, Strauss WE. Vadhan-Raj S, et al. J Blood Med. 2017 Dec 7;8:199-209. doi: 10.2147/JBM.S138474. eCollection 2017. J Blood Med. 2017. PMID: 29263710 Free PMC article.
Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, Huot-Marchand P, Duvillié L, Concas VH, Bugat R. Toledano A, et al. Support Care Cancer. 2016 Jan;24(1):67-75. doi: 10.1007/s00520-015-2728-3. Epub 2015 Apr 29. Support Care Cancer. 2016. PMID: 25921449
Association of Venous Thromboembolism and Early Mortality in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer.
Su Y, Huo M, Hua L, Zhang Y, Yi J, Zhang S, Li J, Zhang Y. Su Y, et al. Cancer Manag Res. 2021 May 18;13:4031-4040. doi: 10.2147/CMAR.S301088. eCollection 2021. Cancer Manag Res. 2021. PMID: 34040443 Free PMC article.

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy - PubMed (original) (raw)